Diagnosis and Management of Vertebrobasilar (Basilar-Type) Migraine
Vertebrobasilar migraine (now termed "migraine with brainstem aura") should be diagnosed based on ICHD-3 criteria requiring at least two attacks with specific brainstem symptoms (dysarthria, vertigo, tinnitus, diplopia, ataxia, bilateral paresthesias, or altered consciousness) accompanied by migraine headache, and managed with standard migraine preventive therapies while avoiding triptans and ergots during acute attacks due to theoretical vasospastic concerns.
Diagnosis
Clinical Criteria
The diagnosis requires identifying specific brainstem-origin symptoms that distinguish this from typical migraine with aura 1:
- At least 2 attacks with aura symptoms clearly originating from the brainstem or both hemispheres simultaneously
- Specific aura symptoms must include at least two of the following:
- Dysarthria (speech disturbance)
- Vertigo
- Tinnitus or impaired hearing
- Diplopia (double vision)
- Ataxia (cerebellar-type)
- Bilateral visual symptoms
- Bilateral paresthesias
- Decreased level of consciousness
- Critically: NO motor weakness (which would indicate hemiplegic migraine instead) 2
- Aura symptoms last 5-60 minutes
- Headache follows within 60 minutes of aura onset
Key Diagnostic Considerations
Red flags requiring urgent investigation 3:
- Atypical aura features suggesting TIA, stroke, or arteriovenous malformations
- Thunderclap headache (subarachnoid hemorrhage)
- Focal neurological symptoms persisting beyond typical aura duration
- Neck stiffness (meningitis, SAH)
- Onset after age 50 years
Differential diagnosis to exclude 1, 4:
- Posterior fossa pathology (tumor, malformation)
- Vertebrobasilar ischemia/stroke
- Complex partial seizures
- CADASIL or MELAS syndromes
- Hemiplegic migraine with cerebellar features
- Meniere's disease (when vertigo predominates)
- Episodic ataxia type 2
Required Investigations
Brain MRI without contrast is recommended for all patients with suspected migraine with brainstem aura 1. This is essential to exclude structural posterior fossa lesions and vascular abnormalities that carry high morbidity and mortality risk.
Additional testing may include:
- Vascular imaging (MRA/CTA) if vascular pathology suspected
- EEG if seizure disorder considered
- Lumbar puncture with CSF analysis in select cases
- Consider that vertebrobasilar artery elongation may be associated with this condition 5
Patient Demographics
This condition primarily affects children, adolescents, and young adults, with onset typically before age 25 and female predominance 2, 1.
Management
Acute Treatment
Critical caveat: Triptans and ergot alkaloids are traditionally contraindicated during attacks of migraine with brainstem aura due to theoretical concerns about vasospasm in the vertebrobasilar circulation 6, 3. However, this contraindication is based on historical vascular theories rather than actual evidence of harm 7, 6.
First-line acute treatment options 3:
- NSAIDs: Acetylsalicylic acid, ibuprofen, or diclofenac potassium
- Use early in the headache phase when pain is still mild
- Antiemetics: Domperidone or metoclopramide for nausea/vomiting
Alternative acute approaches:
- Greater occipital nerve blockade may be effective, particularly when suboccipital tenderness is prominent 7
- Vestibular suppressants for prominent vertigo 4
Medications to avoid 3:
- Oral ergot alkaloids (poorly effective and potentially toxic)
- Opioids and barbiturates (questionable efficacy, risk of dependency and medication overuse headache)
Preventive Treatment
Preventive therapy should be considered when attacks adversely affect quality of life on ≥2 days per month despite optimized acute treatment 3.
First-line preventive medications 3:
- Beta-blockers without intrinsic sympathomimetic activity: atenolol, bisoprolol, metoprolol, or propranolol
- Topiramate
- Candesartan
Second-line preventive medications 3:
- Flunarizine (particularly useful given calcium channel blocker properties for vertebrobasilar symptoms) 2
- Amitriptyline
- Sodium valproate (contraindicated in women of childbearing potential) 2
Emerging evidence:
- Lamotrigine has shown effectiveness in preventing aura symptoms in basilar-type migraine in case reports 8
- Betahistine may be particularly useful for vertigo prophylaxis 2
Third-line options 3:
- CGRP monoclonal antibodies (erenumab, fremanezumab, galcanezumab, eptinezumab)
- Assess efficacy after 3-6 months
Treatment Duration and Monitoring
- Assess oral preventive medication efficacy after 2-3 months at therapeutic dose 3
- If one preventive fails, try another drug class—failure of one does not predict failure of others 3
- Consider pausing preventive therapy after 6-12 months of successful treatment to determine if it can be discontinued 3
- Measure success by percentage reduction in monthly migraine days
Non-Pharmacological Approaches
Evidence-supported options 3:
- Non-invasive neuromodulatory devices
- Biobehavioral therapy
- Acupuncture (though not superior to sham acupuncture)
- Lifestyle modifications addressing sleep quality and physical fitness 3
Insufficient evidence for: Physical therapy, spinal manipulation, dietary approaches 3
Important Clinical Pitfalls
Do not conflate with hemiplegic migraine: The presence of motor weakness excludes basilar-type migraine and indicates hemiplegic migraine instead 2
Do not delay neuroimaging: Given the broad differential diagnosis with high-mortality conditions, brain MRI is essential 1
Avoid medication overuse: Frequent use of acute medications (≥10 days/month for triptans/combination analgesics, ≥15 days/month for simple analgesics) risks medication overuse headache 3
Recognize comorbid anxiety: Mood disorders, particularly anxiety, are common and should be addressed 4
Patient education is critical: Explain the benign nature of the condition despite dramatic symptoms, proper medication use, and importance of adherence 3
Prognosis
The prognosis is generally favorable 1. Many patients experience improvement with age, as migraine often remits in older adults 3.